Appointments

866.320.4573

Request an Appointment

Questions

800.223.2273

Contact us with Questions

Expand Content

Stephen Ellis, MD

216.444.6697

Stephen Ellis, MD
Department: Cardiovascular Medicine
Location: Cleveland Clinic Main Campus
Mail Code J2-3
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.444.6697
DeskDesk:216.444.6740
WorkFax:216.636.6960
Surgeon:
No
Treats:
Adults Only

Biographical Sketch

Stephen G. Ellis, MD, is the Section Head of Invasive/Interventional Cardiology in the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at the Sydell and Arnold Miller Family Heart & Vascular Institute. He also is co-director and co-founder of the Cardiovascular Genebank. His principal clinical interests are complex coronary interventions, novel treatments for inoperable patients, minimally invasive treatments for aortic vale diseases and studies to better understand the basis and predict the occurrence of disease (genomics and proteomics) .

Board-certified in Internal Medicine, Cardiology and Interventional Cardiology, Dr. Ellis is a member of the American Heart Association's Scientific Council on Arteriosclerosis and Scientific Council on Clinical Cardiology .

He also serves on the editorial boards for numerous publications, including the Journal of the American College of Cardiology American Journal of Cardiology, Circulation and the American Heart Journal. Dr. Ellis has authored and co-authored more than 700 papers on interventional cardiology and cardiovascular disease for scientific journals including the New England Journal of Medicine, Circulation, Journal of the American College of Cardiology and American Journal of Cardiology.

He has also served as the principal investigator for numerous national and international clinical studies that have changed the approach to treatment of coronary artery disease, including the RESCUE I trial, GUSTO IIb PTCA study, TAXUS IV and V trials ,the FINESSE trial and the ABSORB III and IV trials.

A graduate of the University of California (at Los Angeles) Medical School, Dr. Ellis completed his internship and residency at Cedars-Sinai Medical Center in Los Angeles and his fellowships at the Brigham and Women's Hospital (Cardiology) in Boston, Stanford University (Cardiology) in Stanford, Calif., and Emory University (Angioplasty) in Atlanta. He has done additional work in Molecular Biology at Penn State University.

Education & Fellowships

Fellowship - Emory University Hospital
Angioplasty
Decatur, GA USA
1986
Fellowship - Stanford University Hospital
Cardiology
Stanford, CA USA
1985
Fellowship - Brigham & Women's Hospital
Cardiology
Boston, MA
1982
Residency - Cedars-Sinai Medical Center
Internal Medicine
Los Angeles, CA USA
1981
Internship - Cedars-Sinai Medical Center
Internal Medicine
Los Angeles, CA USA
1979
Medical School - University of California-Los Angeles School of Medicine
Los Angeles, CA USA
1978
Undergraduate - Stanford University
Palo Alto, CA USA
1973

Certifications

  • Internal Medicine
  • Internal Medicine- Cardiovascular Disease
  • Internal Medicine- Interventional Cardiology

Specialty Interests

Coronary Artery Disease, Stent Restenosis, Total Coronary Occlusions, Angioplasty, Stent-Coronary, Coronary Artery Atherectomy, Coronary Intervention, Drug Eluting Stenting, Heart Valve Disease - Percutaneous Interventions, Stents

Awards & Honors

  • Regent’s Scholar, University of California, 1973-1976, 1978
  • Distinguished Teaching Awards, 1992, 1996, 2003
  • The Best doctors in America, Cleveland Clinic,  1993-present
  • The Best Doctors in Cleveland, 2001-present
  • NIH funding in acute myocardial infarction, genomics and stem cell research, 2002-present

Additional Training

  • Molecular Biology, Penn State University

Memberships

  • American College of Cardiology, 1985-Present
  • American College of Physicians, 1980-Present
  • American Association for Advancement of Science,1992-Present
  • American Heart Association, Scientific Council on Arteriosclerosis,1995-Present
  • American Heart Association, Scientific Council on Clinical Cardiology,1995-Present

Treatment & Services

  • Abnormal Stress Test
  • Angiogenesis
  • Angiography
  • Angioplasty
  • Aorta Surgery
  • Atherectomy
  • Clinical Trials
  • Coronary Artery Atherectomy
  • Coronary Balloon Angioplasty (PTCA)
  • Coronary Intervention
  • Drug Eluting Stenting
  • Enhanced External Counterpulsation (EECP)
  • FFR determination
  • Hematopoietic Stem Cell Transplantation
  • Interpretation of Genetic Risk Factors: Coronary Artery Disease
  • Intra-aortic Balloon Pumping
  • Optical Coherence Tomography
  • Percutaneous Valve Treatment
  • Pericardiocentesis
  • Preventive Cardiology
  • Rotational Atherectomy
  • Stem Cell Therapy
  • Stents
  • Stress Testing
  • Valve Surgery
  • Virtual Histology

Specialty in Diseases and Conditions

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 8/21/2014, Dr. Ellis has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Ellis receives fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:

  • Abbott Laboratories
  • Boston Scientific Corporation
  • Daiichi Sankyo, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English